Zhanfang Guo

1.6k citations

19 papers · 585 indexed · h-index 11

Molecular Biology
Oncology top 10%
Pulmonary and Respiratory Medicine top 10%
Cancer Research
Genetics

Co-authors: X. Cynthia Jeremy Hoog Matthew J. Ellis Shunqiang Li Rebecca Aft Jingqin Luo Reece Goiffon Christine E. Ryan
Topics: Advanced Breast Cancer Therapies (7 papers)Cancer-related Molecular Pathways (7 papers)Microtubule and mitosis dynamics (5 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Investigation Journal of Clinical Oncology Cancer Research
Partner nations: United States China Australia

In The Last Decade

Zhanfang Guo

18 papers receiving 578 citations

Peers

Countries citing papers authored by Zhanfang Guo

Since Specialization

Citations

This map shows the geographic impact of Zhanfang Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhanfang Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhanfang Guo more than expected).

Fields of papers citing papers by Zhanfang Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhanfang Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhanfang Guo. The network helps show where Zhanfang Guo may publish in the future.

Co-authorship network of co-authors of Zhanfang Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Zhanfang Guo. A scholar is included among the top collaborators of Zhanfang Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhanfang Guo. Zhanfang Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Abstract P2-17-03: Preclinical study of trastuzumab deruxtecan (T-Dxd; DS-8201a) in combination with DNA damage response pathway inhibitors in HER2-low/Hormone receptor negative breast cancer patient-derived xenograft models 2023 ·Cancer Research ·(unknown),Zhanfang Guo,Alice Meroni,Emily Cybulla,Jeremy Hoog,Alessandro Vindigni,X. Cynthia	1
2	Exploring the Mechanism of Realgar against Esophageal Cancer Based on Ferroptosis Induced by ROS-ASK1-p38 MAPK Signaling Pathway 2022 ·Evidence-based Complementary and Alternative Medicine ·(unknown),(unknown),(unknown),Zhanfang Guo,(unknown),Hongyan Zhang,Changrong Zhang	10
3	Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin 2022 ·Molecular & Cellular Proteomics ·(unknown),Petra Erdmann-Gilmore,Jacqueline L. Mudd,Qiang Zhang,R. W. Seymour,Zhanfang Guo,(unknown),S. Peter Goedegebuure,Ye Bi,(unknown),Jennifer Alexander‐Brett,Shunqiang Li,X. Cynthia,Ryan C. Fields,R. Reid Townsend,Jason M. Held	10
4	Allicin Promotes Autophagy and Ferroptosis in Esophageal Squamous Cell Carcinoma by Activating AMPK/mTOR Signaling 2022 ·SSRN Electronic Journal ·Zhanfang Guo,Yanjiao Zhang	1
5	Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN) 2022 ·Cancer Research ·Foluso O. Ademuyiwa,Donald W. Northfelt,Tracey L. O’Connor,Ellis Levine,Jingqin Luo,Tao Yu,Jeremy Hoog,Marie L. Laury,(unknown),(unknown),Zhanfang Guo,(unknown),Katherine N. Weilbaecher,Mateusz Opyrchal,Rebecca Aft,Katherine Clifton,Rama Suresh,Nusayba A. Bagegni,Ian S. Hagemann,X. Cynthia	2
6	Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1 2021 ·Cell Reports ·Cuige Zhu,Sun-Joong Kim,Arshag D. Mooradian,(unknown),Ziqian Li,(unknown),Patrick L. Collins,Keren Wang,Zhanfang Guo,Jeremy Hoog,X. Cynthia,Eugene M. Oltz,Jason M. Held,Jieya Shao	14
7	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models 2020 ·UNC Libraries ·Lin Li,Christine E. Ryan,Aleix Prat,Zhanfang Guo,Matthew J. Ellis,(unknown),(unknown),Helen Piwnica‐Worms,Shunqiang Li,Rebecca Aft,Jeremy Hoog,Reece Goiffon,Shirong Cai	12
8	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models 2020 ·Cancers ·Zhanfang Guo,Tina Primeau,Jingqin Luo,(unknown),Hua Sun,Jeremy Hoog,Feng Gao,Shixia Huang,Dean P. Edwards,Sherri R. Davies,Rebecca Aft,Li Ding,Matthew J. Ellis,Shunqiang Li,X. Cynthia	11
9	PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer 2019 ·Oncotarget ·Sandeep Rajput,Zhanfang Guo,Shunqiang Li,X. Cynthia	9
10	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib 2017 ·Breast Cancer Research ·Nusayba A. Bagegni,Shana Thomas,Ning Liu,Jingqin Luo,Jeremy Hoog,Donald W. Northfelt,Matthew P. Goetz,Andres Forero,Mattias Bergqvist,(unknown),(unknown),Edward M. Suh,Zhanfang Guo,Kiran Vij,Souzan Sanati,Matthew J. Ellis,X. Cynthia	53
11	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·X. Cynthia,César Sánchez,Feng Gao,Robert J. Crowder,Michael Naughton,Timothy Pluard,(unknown),Zhanfang Guo,Jeremy Hoog,A. Craig Lockhart,Austin Doyle,Charles Erlichman,Matthew J. Ellis	62
12	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer 2016 ·Oncotarget ·Sandeep Rajput,(unknown),Zhanfang Guo,Jeremy Hoog,Shunqiang Li,X. Cynthia	60
13	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer 2015 ·Clinical Cancer Research ·X. Cynthia,Jingqin Luo,Michael Naughton,Foluso O. Ademuyiwa,Rama Suresh,Malachi Griffith,Obi L. Griffith,Zachary L. Skidmore,Nicholas C. Spies,Avinash Ramu,Lee Trani,Timothy Pluard,Gayathri Nagaraj,Shana Thomas,Zhanfang Guo,Jeremy Hoog,Jing Han,Elaine R. Mardis,(unknown),Matthew J. Ellis	77
14	A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC). 2014 ·Journal of Clinical Oncology ·X. Cynthia,Feng Gao,Michael Naughton,Timothy Pluard,Steven Sorscher,(unknown),Zhanfang Guo,Farrokh Dehdashti,Ben Ho Park,A. Craig Lockhart,L. Austin Doyle,Matthew J. Ellis,Bracha Erlanger	3
15	Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models 2013 ·Molecular Cancer Therapeutics ·Siguang Xu,Shunqiang Li,Zhanfang Guo,Jingqin Luo,Matthew J. Ellis,X. Cynthia	41
16	A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer 2013 ·Breast Cancer Research and Treatment ·X. Cynthia,Vera J. Suman,Matthew P. Goetz,Paul Haluska,Timothy J. Moynihan,Rita Nanda,Olufunmilayo I. Olopade,Timothy Pluard,Zhanfang Guo,Helen X. Chen,Charles Erlichman,Matthew J. Ellis,Gini F. Fleming	47
17	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models 2012 ·Journal of Clinical Investigation ·X. Cynthia,Shirong Cai,Shunqiang Li,Christine E. Ryan,Zhanfang Guo,W. Timothy Schaiff,Lin Li,Jeremy Hoog,Reece Goiffon,Aleix Prat,Rebecca Aft,Matthew J. Ellis,Helen Piwnica‐Worms	166
18	Clinical and correlative science results in a phase II study of UCN-01in combination with irinotecan in recurrent triple-negative breast cancer (TNBC). 2012 ·Journal of Clinical Oncology ·X. Cynthia,Matthew J. Ellis,Gina R. Petroni,A. Craig Lockhart,Michael Naughton,Timothy Pluard,Christiana Brenin,Joel Picus,(unknown),(unknown),Zhanfang Guo,Shirong Cai,Christine E. Ryan,(unknown),Jeremy Hoog,Janet Dancey,Mark A. Watson,Helen Piwnica‐Worms,Paula M. Fracasso	2
19	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models 2012 ·Journal of Clinical Investigation ·X. Cynthia,Shirong Cai,Shunqiang Li,Christine E. Ryan,Zhanfang Guo,W. Timothy Schaiff,Lin Li,Jeremy Hoog,Reece Goiffon,Aleix Prat,Rebecca Aft,Matthew J. Ellis,Helen Piwnica‐Worms	4

About Zhanfang Guo

Zhanfang Guo is a scholar working on Oncology, Cancer Research and Cell Biology, having authored 19 papers that have together received 585 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (7 papers) and Microtubule and mitosis dynamics (5 papers). The work is most often cited by research in Oncology (335 citations), Cancer Research (154 citations) and Pulmonary and Respiratory Medicine (200 citations). Zhanfang Guo has collaborated with scholars based in United States, China and Australia. Frequent co-authors include X. Cynthia, Jeremy Hoog, Matthew J. Ellis, Shunqiang Li, Rebecca Aft, Jingqin Luo, Reece Goiffon, Christine E. Ryan, Helen Piwnica‐Worms and Aleix Prat. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact